Crossmark

Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data

Crossref DOI link: https://doi.org/10.1007/s00345-026-06237-z

Published Online: 2026-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Jingwen

Fu, Wu

Huang, Jiaying

Liu, Maobai

Cai, Hongfu
License Information

Text and Data Mining valid from 2026-01-31

Version of Record valid from 2026-01-31
More Information

Article History

Received: 29 September 2025

Accepted: 24 January 2026

First Online: 31 January 2026

Declarations

:

: The authors declare no competing interests.

: Not applicable.

: The authors declare that they have obtained written consent from all participants involved in the study to publish the data and findings.

Document is current

Any future updates will be listed below